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T HE difficulties in consistently prolonging sur-
vival after orthotopic liver transplantation have 
been documented by us l and by Calne. l In this report 
we describe a new trial of orthotopic liver transplan-
tation in 14 patients who were scheduled to be treat-
ed with cyclosporin A and prednisone. Two patients 
died during the operation. Ten (83 per cent) of the 12 
patients who survived surgery and received the drugs 
are living after eight to 14 V2 months; another lived for 
a. year, before dying of a recurrence of cholangiocar-
clnoma. 
Although longer follow-up periods and more case 
studies will be required to establish the safety and ef-
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fectiveness of this form of therapy, the exceptionally 
encouraging early results seem attributable to the use 
of cyclosporin A in combination with low doses of 
steroids for immunosuppression. The first use of cy-
closporin A in liver transplantation was reported by I 
Caine et a1. 3 
METHODS 
Fourteen patients (age range, eight to 41 years) were accepted for 
the pilot trial. Liver replacement was attempted between March 10 
and September 28, 1980. Two patients who were scheduled to be 
treated with cyclosporin A plus prednisone died during operation. 
One bled to death from a laceration of the portal vein, and the other 
received a homograft too large to permit the abdomen to be closed. 
Thus only 12 patients were treated with immunosuppression. 
Transplantation 
The general techniques used in these operations have been pre-
viously described. I,. Seven of the 14 livers were removed during op-
erations in cities other than Denver (75 to 2000 miles [120 to 3200 
km] away). All 14 livers were preserved with Collins' solution, as 
described by Benichou et al. 5 Ischemia lasted from 1 Y2 to 10 Y2 
hours. Biliary-tract reconstruction was performed through duct-
to-duct, gallbladder-to-jejunal-Roux-limb, and common-duct-to-
Roux-limb anastomosis, in that order of frequency. 
Selection of Recipients and Donors 
Of the 12 patients who survived the operation, three had chronic 
aggressive hepatitis and three had the Budd-Chiari syndrome. The 
following diseases were present in one patient each: primary bili-
ary cirrhosis, secondary biliary cirrhosis, sclerosing cholangitis, 
hepatoma, Byler's disease, and intrahepatic atresia. Of the two pa-
tients who died during operation, one had sclerosing cholangitis 
and the other had secondary biliary cirrhosis (caused by a gunshot 
wound to the hepatic hilum). 
Each donor was blood-group compatible with each respective re-
cipient. There were no positive T-cell or B-cell cytotoxic cross 
matches at warm temperatures. In the 12 surviving patients, mis-
matches at the A and B loci averaged 3.3±0.7 (S.D.) and matches 
averaged 0.6±0.S. The number of matching DR loci ranged from 0 
to I (mean, 0.4). 
Immunosuppression 
Cyclosporin A treatment was started on the day of operation 
(17.5 mg per kilogram of body weight per day, given intramus-
cularly or by mouth). After six to eight weeks the doses were 
reduced to 10 mg per kilogram per day or less. In the first few pa-
tients Crable 1), prednisone was not given until rejection super-
vened. In the other patients, either prednisone was administered in 
low doses on the day of operation or, in adults, 200 mg was given on 
the day of operation. When the 200-mg dose was given, prednisone 
was reduced by decrements of 40 mg daily for four days. On the 
fifth day a further decrease of 20 mg was made. Later reductions in 
maintenance doses of prednisone were made according to the pa-
tient's course and body weight. 
Table 1. Prednisone Dosage in Liver-Transplant Recipients 
Given Cyclosporin A Immunosuppression. 
PREDNISONE DOSAGE 
No initial dose • 
Low initial dose « I mg/kg body wI) 
Short cycle of doses t 
PATIENT Nos. 
1,2,3,4,5,10 
8,12 
6,7,9,11 
TOTAL 
6 
2 
4 
·Prednisone therapy was started in all patients within six to 60 days because of faulty 
liver function, 
tSee Methods - Immunosuppression. 
t 
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MONTHS AFTER TRANSPLANT 
Figure 1. One-Year Actuarial Survival in Patients Given Liver 
Transplants. 
The follow-up period ranged from eight to 14% months. The 
figures above the symbols denote the numbers of patients 
alive at different intervals. 
The open circles represent survival in the 12 patients who 
lived through the operation and were treated with cyclo-
sporin A and prednisone, the solid circles represent survival 
in all 14 patients who underwent transplantation (including 
the two who died during the operation), and the crosses rep-
resent survival in 170 patients from a previous series who 
were treated with conventional immunosuppressants. 
At the slightest indication of liver-graft dysfunction, aggressive 
diagnostic steps were taken, including biopsy and transhepatic 
cholangiography. 
Pathological Studies In Survivors of Operation 
Tissue specimens were obtained at autopsy in one patient and by 
hepatic biopsy in eight others. The number of biopsies of individ-
ual liver homografts ranged from one to five, with an overall total of 
17. The tissue was examined with light and electron microscopy 
and with the immunoperoxidase technique. 
RESULTS 
Survival 
Survival of a graft was concomitant with survival of 
its recipient. Of 12 patients who survived operation 
and who could be treated with immunosuppression, 
10 (83 per cent) are still living after 12.1±2.4 months 
(±S.D.). When the two recipients who died during 
i operation are also considered, the survival rate is 71 
per cent. The only early postoperative death was that 
of a child 19 days after transplantation; the hepatic 
artery of the homograft had thrombosed. 
The patient whose original diagnosis was thought 
to be sclerosing cholangitis had a metastatic cholan-
giocarcinoma in the subhepatic space; this tumor was 
diagnosed 10 months after operation. Her native liver 
was reexamined and found to contain part of the same 
tumor. She died one year after transplantation. 
Of the eight recipients who have lived for a year 
since transplantation, seven are still alive, although 
recurrent Budd-Chiari syndrome developed in one 14 
months after operation. The actuarial life-survival 
curves for the first year of survival are shown in Fig-
ure 1, with and without the two patients who died 
during operation and who never received immuno-
suppressants. The improvement over our previous re-
sults in liver replacement is striking (Fig. 1). 
One of the patients who passed the one-year mark 
had an advanced hepatoma with tumor invasion of the 
retrohepatic inferior vena cava. The absence of a re-
currence is surprising in view of our discouraging ear-
lier experience under such circumstances. 1 
Morbidity 
Two of the recIpients required secondary conver-
sion of cholecystojejunostomy to choledochojejunos-
tomy. These revisions of biliary-tract drainage were 
made in one recipient at four weeks and in the other at 
five weeks after transplantation. 
One patient had a cardiac arrest a few hours after 
transplantation. She has recovered mentally but still 
has residual locomotor abnormalities that are slowly 
lessening a year later. 
A recipient whose original hepatic disease was the 
Budd-Chiari syndrome had mesenteric-vein infarc-
tion that required partial intestinal resection. She re-
quired more than three months of ventilatory support 
because of an acute and chronic respiratory-distress 
syndrome, from which there developed a pleural com-
plication necessitating decortication. The Budd-Chi-
ari syndrome recurred more than a year after trans-
plantation, and thus her prognosis is guarded. 
One woman had an accident after returning home 
and fractured two ribs, the right humerus, the pelvis, 
the left hip, the right femur, and three vertebras. Re-
placement of the left hip and internal fixation of a 
right-femoral-shaft fracture were required. Bone 
fragility secondary to longstanding secondary cirrho-
sis contributed to the severity of her injuries. 
Another woman had subphrenic and subhepatic 
abscesses that were treated with drainage, a duo-
denal ulcer that was treated with vagotomy and 
pyloroplasty, and an intrasplenic abscess that was 
treated with splenectomy. 
All the surviving patients except the one with re-
current Budd-Chiari syndrome now live outside of the 
hospital. The postoperative hospitalization periods 
averaged 75.5±57.6 days (range, 23 to 210 days; me-
dian, 61 days). 
Liver Function and Immunosuppression 
Current liver functioning and the maintenance 
doses of cyclosporin A and prednisone are given in 
Table 2. Most of the recipients have never been given 
more than 20 mg of prednisone per day for longer 
than five or six days. The ultimate maintenance doses 
of cycJosporin A were influenced by the presence or 
absence of abnormalities in renal function. When rises 
. I 
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Table 2. Current Liver Function and Maintenance Therapy in 10 Patients.· 
PATIENT 
No. 
AGEl SEX TIM! A.fTER 
SUIOEJ,y 
CURRENT LIVER FUNCTION SERUM 
CREATININE 
MAINTENANCE THERAPY 
SERUM ALKAUNE SOOT" CYCLOSPORIN PUDNISONE' 
BluaUIIN PHOPHATASE 
"'" 
""ldJ 
l"",oIlli"" 
I 28/F 141'1 1.2 (20.S) ISS 
2 251M 141'1 1.3 (22.2) 477 
37/F 14 0.5 (8.6) 136 
4t 2O/F 14 2.2 (37.6) 55 
5 41/F \31'1 0.3 (5.1 ) 332 
261M 121'1 1.2 (20.5) 141 
8 21/F 12 1.1 (18.8) 52 
9 16/F 9 1.7 (29.1) lSI 
10 28/F 9 2.4 (41.0) 220 
12 10/F 0.8 (13.7) 863 
-Serum upartatc aminotransferase. 
in creatinine and blood urea nitrogen seemed relat-
ed to nephrotoxicity from cyclosporin A, the doses of 
cyclosporin were reduced gradually to a nontoxic 
level. 
Pathological Findings 
The biopsies, usually performed because of postop-
erative liver-function abnormalities, revealed a vari-
ety of findings, of which the most common was acute 
cellular rejection (Table 3) Cellular rejection of a 
transplant was always responsive to increased steroid 
therapy. 
Table 3. Histopathologic Findings In Nine Patients. 
PATIENT DATE OF tho TE OF FINDINGS 
~o OPERATION BIOP'1v 
9 March 1980 9 May 1980 M lid cellular rejection 
6 Aug 1980 Few tiny foci of necrosis; otherwise 
normal 
2 10 March 1980 I Apnl1980 Acute cellular rejection 
16 April 1980 Cytomegalovirus hepatitIS 
30 Apnl1980 Recovenng from cytomegalovIrus 
hepatitis 
II June 1980 Very early fibrosis 
18 Sept 1980 As In fourth biopsy. but with 
superimposed acute cellu· 
lar rejeclton 
21 March 1980 22 April 1980 Acute cellular rejection 
II June 1980 Low·grade cellular rejection 
4 25 March 1981 10 May 1981 Recurrent Budd-Chiari syndrome 
13 April 1980 30 April 1980 Acute cellular rejection 
6 May 1980 Acute ceUul.ar rejection 
6 14 May 1980 II June 1980 Acute cellular rejection 
6 March 1981 Normal 
9 5 June 1980 2 March 1980 Acute cellular rejection 
II 17 Scpl1980 5 Oct 1980' Widespread liver necrosis t 
12 28 Sept 1980 14 Oct 1980 Small focal infarcts" cholangitil 
4 Nov 1980 Early fibrosis .t changes luggestive 
of lOme bile-duct obsuuction 
• Date of aUlOpty. 
tHepauc-anery thromboola. 
wUIJII/,., 
21 
48 
35 
10 
93 
38 
26 
49 
67 
39 
mrldJ 
Emmof//jf~" 
1.6 (141) 
1.8 (159) 
1.0 (88) 
4.6 (407) 
1.3 (lIS) 
2.0 (177) 
1.0 (88) 
1.3 (115) 
1.6 (141) 
0.5 (44) 
mrlkglday "'r/day 
7.9 20 
5.1 IS 
9.S 10 
5.1 5 
9.1 10 
9.8 10 
6.8 IS 
9.8 10 
7.7 12.5 
7.1 10 
tTbil palient hu recurrent Budd-Chiari syndrome with secondary renal dysfunction. 
DISCUSSION 
The follow-up period in this small number of pa-
tients is still short. However, it is unlikely that the 
striking improvement in the early results after liver re-
placement could be a statistical accident. The trans-
plant rejections that were seen in these patients were 
common, but they were easy to control with small in-
creases in prednisone. The same phenomenon has 
been noted in recipients of kidney homografts, whose 
prognosis has also been markedly improved by thera-
py with cyclosporin A and prednisone, as compared 
with conventional immunosuppression. 6 Like pre-
vious patients, the liver recipients described in this 
paper had major complications; a new feature was the 
ability to treat complications successfully in patients 
whose livers were functioning well and who were given 
low doses of prednisone. 
The histopathologic features of the relatively self-
limited and easily treated rejection during therapy 
with cyclosporin A and prednisone were compared 
with the features of rejection during conventional im-
munosuppression. There was only one striking differ-
ence - the presence of a high proportion (5 to 20 per 
cent) of eosinophils in the cellular infiltrate. There 
was no evidence of long-term rejection, and no hepat-
ic arteriolar or arterial lesions. 
Successful use of cyc1osporin A in liver transplan-
tation depended on a thorough understanding of the 
drug's toxicity. Injury to the kidney and liver was 
monitored with the idea of reducing the dose when in-
dicated. The toxic propenies of cyc1osporin A were 
not serious enough to prevent its long-term use in all 
the surviving patients. There was no occurrence of 
de novo neoplasms (including lymphomas). One pa-
tient, who received a transplant because of an ad-
vanced hepatoma, has so far escaped the kind of re-
currence that followed all our previous attempts at 
transplantation for this indication and that was con-
firmed in the recipient in this series whose native liver 
contained a cholangiocarcinoma. 
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